High Prevalence Mutations in \textit{ALMS1} in Spanish Alström Patients

Brais Bea Mascato  
Universidade de Vigo Facultad de Biologia  
https://orcid.org/0000-0003-1588-2897

Carlos López Solarat  
Universidade de Vigo Facultad de Biologia

Irene Perea Romeo  
Hospital Universitario Fundacion Jimenez Diaz

Teresa Jaijo  
Instituto de Investigacion Sanitaria La Fe

Fiona Blanco Kelly  
Hospital Universitario Fundacion Jimenez Diaz

Carmen Ayuso  
Hospital Universitario Fundacion Jimenez Diaz

Diana Valverde (✉ dianaval@uvigo.es)  
https://orcid.org/0000-0002-7024-1657

Research

Keywords: ciliopathies, Alström syndrome, metabolic disease

Posted Date: July 28th, 2020

DOI: https://doi.org/10.21203/rs.3.rs-45421/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License.  Read Full License
Abstract

Background:
Alström syndrome (ALMS) is a rare disease with an estimated prevalence lower than 1 in 1,000,000. It is associated with mutations in the Alström syndrome 1 (ALMS1) gene, which encodes a structural protein of the basal body and centrosomes. Symptomatology involves nystagmus, type 2 diabetes mellitus (DM2), obesity, dilated cardiomyopathy (DMC), neurodegenerative disorders and multi-organ fibrosis.

Methods:
We included the clinical data of 13 patients from 12 families, all of them from Spain. We studied the allelic frequency for the different mutations present in this cohort and we perform a haplotype analysis for the most prevalent allele.

Results:
Two alleles were detected in high frequency: p.(Tyr1714Ter) (0.25) and p.(Ser3872TyrfsTer19) (0.167). The segregation analysis of the mutation p.(Tyr1714Ter) in 3 families shows that it is linked to a rare missense polymorphism. Also, we detect an ancestral haplotype for ALMS1 in three families.

Conclusion:
Mutation p.(Tyr1714Ter) co-segregates with a rare single nucleotide polymorphism (SNP) that could be arise by a founder effect in the Iberian Peninsula.

Introduction
Alström Syndrome (ALMS; OMIM #203800) is considered an ultra-rare disorder, with an estimated prevalence lower than 1 in 1,000,000 in European-descent populations and over 800 cases described worldwide, of which 13 patients have been diagnosed in Spain1–4. As in the case of other rare syndromes, consanguineous and/or geographically isolated populations refer higher frequency values5–7. ALMS is also a pleiotropic and multisystemic disorder that is characterized by high inter- and intra-familial variability, regarding the phenotype displayed and the age of onset and severity of symptoms1,2. Cardinal features include childhood obesity, insulin resistance, cone-rod retinal dystrophy, sensorineural hearing loss, type 2 diabetes mellitus (DM2), hypertriglyceridemia and dilated cardiomyopathy (DMC). Other features include hepatic, renal and pulmonary dysfunction, absence seizures or multi-organ fibrosis. The first clinical feature, corresponding to visual dysfunction, usually develops during the first year of life or even within a few weeks after birth with photophobia and nystagmus2. The remaining signs evolve slowly during childhood, although the most severe features can be detected before the first decade1.

The clinical diagnosis of ALMS is based on the presence of primary and secondary features, considering the age of onset throughout development8. ALMS is a monogenic disorder caused by mutations in ALMS1 gene (MIM #606844) and that represents an unusual phenomenon among ciliopathies. ALMS1 is located on chromosome 2 (region 2p13.1), consists of 224 kilobases (kb) and contains 23 coding exons9,10. Several splicing isoforms have been reported, which could produce different protein isoforms with specific functions9,11–13.

To date, over 270 pathogenic variants have been involved in ALMS development, of which 96% are nonsense or frameshift changes (insertions and deletions) that could originate truncated, non-functional proteins if translated1,14. Remarkably, causal changes in the 5' half of the ALMS1 gene coding region (exons 1-7) are practically unreported, which suggests that mutations in this region could be embryonically lethal2. On the contrary, most of deleterious variants are clustered in exons 8 (6.1 kb), 10 (1.9 kb) and 16 (1.2 kb), which are considered mutational hotspots as they comprise 85-97% of the total mutational load for ALMS1 in the different cohorts reported1,7. Hence, direct sequencing of these three exons represented the standard strategy when ALMS is suspected. However, the progressive implementation of high-throughput sequencing (HTS) techniques, such as whole-exome sequencing and targeted gene panels, is replacing the classical approach to ALMS molecular diagnosis15-17.

Although the vast majority of mutations in ALMS1 have been described once, several populations shown a founder effect like English or Turkish population7,18. The knowledge of the mutational load in this gene could be of great interest to understand the phenotype correlation and the molecular basis of this disorder.

Families And Methods

Cohort description
Thirteen patients from 12 unrelated families clinically diagnosed with AS were included in this study. Here we report the genetic characterization of 5 males and 8 females. Table 1.
Table 1.
Summary the genotype of patients, his LOVD ID and the author that described the case

| Families | Lovd number patronente | Author | ALMS1 Mutation 1 c.DNA | ALMS1 Mutation 1 Protein | ALMS1 Mutation 2 c.DNA | ALMS1 Mutation 2 Protein |
|----------|------------------------|--------|-------------------------|--------------------------|-------------------------|--------------------------|
| GBB-28   | -                      | -      | c.2785G>T (Exon8)       | p.(Glu929Ter)            | c.2785G>T (Exon8)       | p.(Glu929Ter)            |
| RP-1232  | -                      | -      | c.4249del (Exon8)       | p.(Arg1417GlyfsTer55)    | c.4249del (Exon8)       | p.(Arg1417GlyfsTer55)    |
| FRPN36   | 1661                   | Piñeiro 2012 | c.5142T>G (Exon8) | p.(Tyr1714Ter)       | c.1844C>G (Exon 8)     | p.(Ser615Ter)           |
| GAS-37   | 1805                   | Marshall 2015 | c.5142T>G (Exon 8) | p.(Tyr1714Ter)       | c.4271T>G (Exon 8)     | p.(Leu1424Ter)          |
| GAS-38   | 1805                   | Marshall 2015 | c.5142T>G (Exon 8) | p.(Tyr1714Ter)       | c.4271T>G (Exon 8)     | p.(Leu1424Ter)          |
| GBB-46   | -                      | -      | c.5142T>G (Exon 8)     | p.(Tyr1714Ter)       | c.5142T>G (Exon 8)     | p.(Tyr1714Ter)          |
| GBB-44   | 1754                   | Marshall 2015 | c.5142T>G (Exon 8) | p.(Tyr1714Ter)       | c.11615_11616del (Exon 17) | p.(Ser3872TyrfsTer19) |
| UG-26225 | -                      | -      | c.5420_5423del (Exon 8) | p.(His1808GlufsTer20) | c.5420_5423del (Exon 8) | p.(His1808GlufsTer20) |
| RP-2186  | 177                    | Marshall 2015 | c.7568_7569del (Exon 9) | p.(His2523ArgfsTer11) | c.4474G>T (Exon 8)     | p.(Glu1492Ter)          |
| GAS-39   | 1747                   | Marshall 2015 | c.10754dup (Exon 16) | p.(Lys3585LysfsTer15) | -                     | -                       |
| RP-793   | 1663                   | Piñeiro 2012 | c.10787_10788del (Exon 16) | p.(Val3596GlufsTer4) | c.10787_10788del (Exon 16) | p.(Val3596GlufsTer4) |
| GBB-45   | -                      | -      | c.11615_11616del (Exon 17) | p.(Ser3872TyrfsTer19) | c.11615_11616del (Exon 17) | p.(Ser3872TyrfsTer19) |
| RP-2177  | -                      | -      | c.11615_11616del (Exon 17) | p.(Ser3872TyrfsTer19) | c.805C>T (Exon 5)      | p.(Arg269Ter)          |

ERG: Electroretinogram; DM2: Type 2 Diabetes Mellitus; DCM: Dilated Cardiomyopathy; CHF: Congestive Heart Failure.

Clinical history from families were obtained through collaboration with medical doctors and the National Association of Alström syndrome Spain. Main clinical characteristics are described in Table 2.
Table 2.
Phenotype summary based on diagnostic criteria for Alström syndrome according to Marshall et al. (2007) for 11 of the 13 cases. Clinical histories of patients GAS-39 was not achieved. x: presence of symptom. -: absence of symptom.

| Families | Vision (history of nystagmus in infancy/childhood, legal blindness, cone and rod dystrophy by ERG) | Obesity and/or insulin resistance and/or DM2 | History of DCM/CHF | Hearing loss | Hepatic dysfunction | Renal failure | Short stature | Males: hypogonadism; Females: irregular menses and/or hyperandrogenism | Thyroid Disorders | Mutations |
|----------|--------------------------------------------------|------------------------------------------|-------------------|-------------|-------------------|--------------|--------------|---------------------------------------------------------------|--------------------|----------|
| GBB-28   | x                                                 | x                                        | -                 | -           | -                 | -            | -            | -                                                             | -                  | p.(Glu929Ter) |
| RP-1232  | x                                                 | x                                        | -                 | -           | -                 | x            | -            | -                                                             | -                  | p.(Arg1417Gl) |
| FRPN36   | x                                                 | -                                        | x                 | x           | -                 | -            | -            | -                                                             | -                  | p.(Tyr1714Te) |
| GAS-37   | x                                                 | x                                        | x                 | x           | -                 | x            | -            | -                                                             | -                  | p.(Tyr1714Te) |
| GAS-38   | x                                                 | -                                        | x                 | x           | -                 | x            | -            | -                                                             | -                  | p.(Tyr1714Te) |
| GBB-46   | x                                                 | -                                        | x                 | x           | -                 | x            | -            | -                                                             | -                  | p.(Tyr1714Te) |
| GBB-44   | x                                                 | x                                        | x                 | x           | -                 | -            | -            | -                                                             | -                  | p.(Tyr1714Te) |
| UG-26225 | x                                                 | x                                        | -                 | -           | -                 | -            | -            | -                                                             | -                  | p.(His1808Gl) |
| RP-2186  | x                                                 | x                                        | -                 | -           | -                 | -            | -            | -                                                             | -                  | p.(His2523Argf) |
| RP-793   | x                                                 | x                                        | x                 | x           | -                 | x            | -            | -                                                             | -                  | p.(Val3596fsGl) |
| RP-2177  | -                                                 | x                                        | x                 | x           | -                 | -            | -            | -                                                             | -                  | p.(Ser3872Tyf) |

ERG: Electroretinogram; DM2: Type 2 Diabetes Mellitus; DCM: Dilated Cardiomyopathy; CHF: Congestive Heart Failure.

This study was approved by the Galician Ethical Committee for Clinical Research (Spain 2006/08) and adhered to the tenets of the Declaration of Helsinki. Informed consent was obtained from all patients or their guardians.

Mutations in these families were described elsewhere 1 and, as part of the Spanish ciliopathy cohort they have been studied by our group 3,4.

Mutations were previously described in these patients but we reanalyzed the cohort and confirmed on an independent PCR reaction and identified in both forward and reverse strands. All the mutations in these patients lead to premature stop codon, resulting in a truncated ALMS1.

**Methods:**

**DNA extraction and Sanger Sequencing:**

DNA was extracted from peripheral blood from participants and available family members. We used the Flexigene DNA kit 250 (Qiagen, Hilden, Germany), following the manufacturer's protocol.

Then DNA extraction, we analysed the exonic DNA of ALMS1. We amplified the DNA by polymerase chain reaction (PCR) in a MJ MiniTM Gradient Thermal Cycler (Bio-Rad, Hercules, CA) with primers described by Collin et al [9]. Then we purify PCR products using ExoSAP (Thermo-Fisher, USA) in a final volume of 6µL. The products were sequenced directly using the BigDye® Terminator v1.3 Cycle Sequencing Kit (Life technologies, Foster City, CA) in a 10-µl reaction. Sequencing products were precipitated, dried and resolved in an ABI PRISM 3130 (Life technologies, Foster City, CA) genetic analyser.

Finally, for nucleotide and amino acid numbering of mutations the reference sequence for ALMS1 (ENST00000613296.5/NM_015120.4) was used.

**Results**

From 12 families we have 13 patients, 5 males and 8 females. All of them have a positive molecular diagnosis, and according to a recessive model, biallelic mutations.
In all cases except in one family, we established two pathogenic mutations. Six of them showed a homozygous mutation pattern, but none referred consanguinity. Families with the same mutation did not refer any relationship between them and came from different locations far away from each other.

Twelve different mutations were detected (Table 1), being homozygous six patients from families: GBB-45, GBB-46, RP-793, RP-1232, GBB-28 and UG-26225. One mutation is located in exon 5, seven mutations are located in exon 8, one in exon 9, two in exon 16 and one in exon 17 of ALMS1, all of them leading to a stop codon. Mutation p.(Tyr1714Ter) in exon 8 has a high frequency between our pool of patients 23.1%, appearing 5 times in 4 patients (one homozygous and three compound heterozygous). Mutation p.(S3872TyrfTer19) have been detected four times in three patients, one homozygous, raising a 15.4% frequency. Most of the mutations were not shown in the ExAc database, no population information was available. Some of the mutations have been load into LOVD database from REWBA project, from the labs where the molecular analysis was performed.

For the data found, mutation p.(Tyr1714Ter) has been described 5 times\textsuperscript{1,14} including three of our samples. Mutations p.(Ser3872TyrfTer19) and p. (Val3596GlufsTer4) have been described 3 times\textsuperscript{1,8}, one heterozygous sample for p.(Ser3872TyrfTer19) reported is one of our patients.

All patients included in this study, present some kind of visual disorders. Obesity, insulin resistance or DM2 were present in 91% of the cases. DMC was found in 8 of 11 patients (73%). Hearing loss was reported in 8 of 11 patients (73%). (Table 2).

A second group of symptoms with low incidence was reported too: Hepatic dysfunction (45%), short stature (45%), thyroid disorders (55%) and hypogonadism/irregular menses 27. (Table 2).

**Relative allele frequencies:**

We detected two specific alleles with high frequency in ALMS1: p.(Tyr1714Ter) and p.(Ser3872TyrfTer19), being only homozygous one family for each of those mutations. Relative frequencies of these alleles in the cohort were 0.231 and 0.154 respectively. (Figure 1).

**Segregation study:**

In patients carrying the p.(Tyr1714Ter) mutation we detected a single nucleotide polymorphism (SNP) with a low frequency (0.017) in European population. This SNP (rs45608038) is located in the Exon 8 of ALMS1. (Supp.Table 1). Thus, we evaluated in 3 families if the presence of this SNP segregates with the mutation p.(Tyr1714Ter), we concluded that this SNP is linked to the mutation. (Figure 2).

**Haplogroup classification:**

To complete the analysis and determinate if this was a common allele, we included the SNPs described by Scheinfeldt\textsuperscript{19} to classify the haplogroup of these patients. The three patients carrying p.(Tyr1714Ter) show the ancestral haplotype described for ALMS1. Thus, we conclude that it is probably a founder mutation. (Table 3).

| Protein Mutation | SNPs             | Exon | GBB-44 | FRPN36 | GBB-46 | Common allele |
|------------------|------------------|------|--------|--------|--------|---------------|
| p.(Phe730=)      | rs7598901        | 8    | T/T    | T/T    | T/T    | T             |
| p.(Gly1415Val)   | rs6546837        | 8    | G/G    | C/G    | G/G    | G             |
| p.(Ile1876Val)   | rs6546838        | 8    | A/A    | G/A    | A/A    | A             |
| p.(Ser2112Arg)   | rs6724782        | 8    | T/T    | A/T    | T/T    | T             |
| p.(Arg2285Leu)   | rs6546839        | 8    | G/G    | C/G    | G/G    | G             |
| p.(Arg2827Ser)   | rs2056486        | 10   | G/G    | G/G    | G/G    | G             |
| p.(Asn2857Ser)   | rs10193972       | 10   | A/A    | A/A    | A/A    | A             |
| p.(Asn1787Asp)*  | rs45608038       | 8    | A/G    | A/G    | G/G    | G             |

**Discussion**

Alström Syndrome is a complex disease that affect multiple organs and induce metabolic disorder. Its huge heterogeneity symptomatology inter-patients and its low incidence in the worldwide population is a great difficulty to perform phenotype genotype correlations.

Until now, more than 270 mutations have been described for ALMS1 related to ALMS. A great percentage of cases harbour private mutations.
In our cohort, we analysed 13 patients with causal ALMS mutations. Most of them have been described previously. We have detected two mutations with high prevalence within our cohort. Both mutations, p.(Ser3872TyrfsTer19) and p.(Tyr1714Ter), generate a premature stop codon resulting in a truncated protein. They are located in exon 17 and 8 respectively. One of these mutations, p.(Tyr1714Ter), co-segregate with a low frequency SNP (rs45608038) in the 3 families analysed (Figure 2), which allows us to established a potential common origin of this allele in the Spanish patients. Also, based on the haplogroups described for ALMS1, this haplotype is grouped with the ancestral one which have been detected in the South of Europe (France, Spain and Portugal) and have a high presence in the African continent. This fact could be interpreted as this ALMS allele was introduced in the Iberian Peninsula from the African continent.

Others SNPs were detected in the FRPN36 proband. Two of them (rs6546839 and rs6724782) are in high frequency in European population (24%) and Latin population (40%). On the other hand, other two SNPs (rs6546838 and rs10193972) are described in the GWAS catalogue, the SNP rs6546838 is associate with an aberrant blood metabolite levels while SNP rs10193972 is associate with the influence of general cognitive function.

In this report, we do not detect any correlation genotype-phenotype in the patients with mutation p.(Tyr1714Ter) and p.(Ser3872TyrfsTer19). Even in two brothers with the same genotype (p.(Tyr1714Ter)/p.(Leu1424Ter); GAS-37, GAS-38), the phenotype was not the same. In this case, GAS-37 report DMC but not his brother.

ALMS is a complex disorder and other factors could be influencing the development of the symptomatology. The prevalence of symptoms like DMC, hepatic dysfunction or hearing loss seems to be conditioned by other unknown agents. Numerous candidate ALMS1-interacting proteins have been reported, that could play a modulating function.

Until now, the exact role of ALMS1 protein it is no clear, and has been detected in other tissues although the basal body location. As pointed out by Braine 2017, some protein isoforms might have distinct intracellular locations and may perform different functions. However, most data support a role for ALMS1 beyond the ciliary function. ALMS1 have been related with several cellular processes including endosomal trafficking, actin organisation and transcription, neuronal migration, maintenance of cellular quiescence, adipogenesis, spermatogenesis, maintenance of pancreatic β cell mass, adaptive thermogenesis, cell cycle arrest of cardiomyocytes and regulation of blood pressure and renal function.

ALMS is a very rare disease that shares clinical features with other ciliopathic syndromes, so clinical diagnosis is quite difficult in some cases. There are about 1,000 patients diagnosed with ALMS around the world. The difficulty to achieve a diagnosis and the lack for a global point of view, makes that some patients still be underdiagnose and seek for medical attendance when the symptoms get worse. An international effort is been made to enrol these patients into national and international associations that keep the patients updated and in touch with clinicians and investigation and will facilitate future observational studies and clinical trials.

**Conclusion**

We detected two high prevalent ALMS1 mutations: p.(Tyr1714Ter) and p.(Ser3872TyrfsTer19) in Spanish cohort. Mutation p.(Tyr1714Ter) co-segregates with a rare SNP that could be arise by a founder effect. Finally, three families with p.(Tyr1714Ter) mutation share the ancestral haplotype for ALMS1 that it is predominant in African continent.

**Abbreviations**

ALMS: Alström syndrome.

CHF: Congestive Heart Failure.

DMC: dilated cardiomyopathy.

DM2: type 2 diabetes mellitus.

ERG: electroretinogram.

HTS: high throughput sequencing.

PCR: polymerase chain reaction.

SNP: single nucleotide polymorphism.

**Declarations**

**Ethics approval and consent to participate:**

This study adhered to the tenets of the Declaration of Helsinki and was approved by an ethics committee (Comité Ético de Investigaciones Clínicas de Galicia, Spain, 2006/08). Informed consent was obtained from all study participants or their guardians after the nature of the procedures to be performed in this study were fully explained.
Consent for publication

Not applicable.

Availability of data and materials:

The data that support the findings of this study are available from the corresponding author, D.V., upon reasonable request.

Competing interests:

The authors declare no conflict of interests.

Funding:

This work was funded by Instituto de Salud Carlos III de Madrid FIS project PI15/00049 and PI19/00332, Xunta de Galicia (Centro de Investigación de Galicia CINBIO 2019-2022) Ref. ED431G-2019/06, Consolidación e estructuración de unidades de investigación competitivas e outras accións de fomento (ED431C-2018/54). Brais Bea-Mascato (ref. FPU17/01567) were recipients of graduate studentship awards (FPU fellowship) from the Spanish Ministry of Education, Culture and Sports.

Authors' contributions:

BB-M, CL-S and DV designed the study. BB-M and CL-S performed the experiments. IP-R, TJ, FB-K and CA collected clinical and genetic data. BB-M, CL-S, CA and DV wrote the manuscript. All authors have read the draft and provided approval for publication.

Acknowledgements

We are very grateful to the ALMS patients and their families for their ongoing cooperation and fully appreciate the collaboration of all colleagues that provided us with clinical information. Thanks, are also given to the Asociación Española del Síndrome de Alström.

Bibliography

1. Marshall JD, Muller J, Collin GB, et al. Alström Syndrome: Mutation Spectrum of ALMS1. *Hum Mutat*. 2015;36(7):660-668. doi:10.1002/humu.22796
2. Marshall JD, Maffei P, Collin GB, Naggert JK. Alström syndrome: genetics and clinical overview. *Curr Genomics*. 2011;12(3):225-235. doi:10.2174/138920211795677912
3. Piñeiro-Gallego T, Cortón M, Ayuso C, Baiget M, Valverde D. Molecular approach in the study of Alström syndrome: analysis of ten Spanish families. *Mol Vis*. 2012;18:1794-1802. https://www.ncbi.nlm.nih.gov/pubmed/22876109.
4. Sanchez-Navarro I, R. J. da Silva L, Blanco-Kelly F, et al. Combining targeted panel-based resequencing and copy-number variation analysis for the diagnosis of inherited syndromic retinopathies and associated ciliopathies. *Sci Rep*. 2018;8(1):5285. doi:10.1038/s41598-018-23520-1
5. Marshall JD, Ludman MD, Shea SE, et al. Genealogy, natural history, and phenotype of Alström syndrome in a large Acadian kindred and three additional families. *Am J Med Genet*. 1997;73(2):150-161. doi:10.1002/(SICI)1096-8628(19971212)73:2<150::AID-AJMG9>3.0.CO;2-Y
6. Aldahmesh MA, Safieh LA, Alkuraya H, et al. Molecular characterization of retinitis pigmentosa in Saudi Arabia. *Mol Vis*. 2009;15:2464-2469. https://www.ncbi.nlm.nih.gov/pubmed/19956407.
7. Ozantürk A, Marshall JD, Collin GB, et al. The phenotypic and molecular genetic spectrum of Alström syndrome in 44 Turkish kindreds and a literature review of Alström syndrome in Turkey. *J Hum Genet*. 2014;60:1. https://doi.org/10.1038/jhgc.2014.85.
8. Marshall JD, Beck S, Maffei P, Naggert JK. Alström Syndrome. *Eur J Hum Genet*. 2007;15:1193. https://doi.org/10.1038/sj.ejhg.5201933.
9. Collin GB, Marshall JD, Ikeda A, et al. Mutations in ALMS1 cause obesity, type 2 diabetes and neurosensory degeneration in Alström syndrome. *Nat Genet*. 2002;31:74. https://doi.org/10.1038/ng867.
10. Hearn T, Renforth GL, Spalluto C, et al. Mutation of ALMS1, a large gene with a tandem repeat encoding 47 amino acids, causes Alström syndrome. *Nat Genet*. 2002;31:79. https://doi.org/10.1038/ng874.
11. Collin GB, Cyr E, Bronson R, et al. Alms1-disrupted mice recapitulate human Alström syndrome. *Hum Mol Genet*. 2005;14(16):2323-2333. http://dx.doi.org/10.1093/hmg/ddi235.
12. Hearn T, Spalluto C, Phillips VJ, et al. Subcellular Localization of ALMS1 Supports Involvement of Centrosome and Basal Body Dysfunction in the Pathogenesis of Obesity, Insulin Resistance, and Type 2 Diabetes. *Diabetes*. 2005;54(5):1581 LP - 1587. doi:10.2337/diabetes.54.5.1581
13. Braune K, Volkmers I, Staege MS. Characterization of Alstrom Syndrome 1 (ALMS1) Transcription Variants in Hodgkin Lymphoma Cells. *PLoS One*. 2017;12(1):e0170694. https://doi.org/10.1371/journal.pone.0170694.
14. Astuti D, Sabir A, Fulton P, et al. Monogenic diabetes syndromes: Locus-specific databases for Alström, Wolfram, and Thiamine-responsive megaloblastic anemia. *Hum Mutat*. 2017;38(7):764-777. doi:10.1002/humu.23233
15. Wang X, Wang H, Cao M, et al. Whole-exome sequencing identifies ALMS1, IQCB1, CNGA3, and MYO7A mutations in patients with Leber congenital amaurosis. *Hum Mutat*. 2011;32(12):1450-1459. doi:10.1002/humu.21587

16. Katagiri S, Yoshitake K, Akahori M, et al. Whole-exome sequencing identifies a novel ALMS1 mutation (p.Q2051X) in two Japanese brothers with Alström syndrome. *Mol Vis*. 2013;19:2393-2406. https://www.ncbi.nlm.nih.gov/pubmed/24319333.

17. Long PA, Evans JM, Olson TM. Exome sequencing establishes diagnosis of Alström syndrome in an infant presenting with non-syndromic dilated cardiomyopathy. *Am J Med Genet A*. 2015;167A(4):886-890. doi:10.1002/ajmg.a.36994

18. Marshall JD, Hinman EG, Collin GB, et al. Spectrum of ALMS1 variants and evaluation of genotype-phenotype correlations in Alström syndrome. *Hum Mutat*. 2007;28(11):1114-1123. doi:10.1002/humu.20577

19. Scheinfeldt LB, Biswas S, Madeoy J, Connelly CF, Schadt EE, Akey JM. Population genomic analysis of ALMS1 in humans reveals a surprisingly complex evolutionary history. *Mol Biol Evol*. 2009;26(6):1357-1367. doi:10.1093/molbev/msp045

20. Burkhardt R, Kirsten H, Beutner F, et al. Integration of Genome-Wide SNP Data and Gene-Expression Profiles Reveals Six Novel Loci and Regulatory Mechanisms for Amino Acids and Acylcarnitines in Whole Blood. *PLoS Genet*. 2015;11(9):e1005510-e1005510. doi:10.1371/journal.pgen.1005510

21. Davies G, Lam M, Harris SE, et al. Study of 300,486 individuals identifies 148 independent genetic loci influencing general cognitive function. *Nat Commun*. 2018;9(1):2098. doi:10.1038/s41467-018-04362-x

22. Hearn T. ALMS1 and Alström syndrome: a recessive form of metabolic, neurosensory and cardiac deficits. *J Mol Med*. 2018. doi:10.1007/s00109-018-1714-x

23. Jaykumar AB, Caceres PS, King-Medina KN, et al. Role of Alström syndrome 1 in the regulation of blood pressure and renal function. *JCI insight*. 2018;3(21):e95076. doi:10.1172/jci.insight.95076

24. Van Groenendael S, Giacovazzi L, Davison F; et al. High quality, patient centred and coordinated care for Alstrom syndrome: a model of care for an ultra-rare disease. *Orphanet J Rare Dis*. 2015;10(1):149. doi:10.1186/s13023-015-0366-y

**Figures**

![Figure 1](image-url)
Different relative allele frequencies for the mutations detected in the cohort expressed as a fraction of total alleles (n=26).

Figure 2

Representation of pedigree of 3 families. a) Representation of a mother carrier of the rare SNP and the causal mutation (heterozygosis). b) Representation of a father carrier of the rare SNP and the causal mutation (heterozygosis). c) Representation of proband with rare SNP and the causal mutation (homozygosis).

*: rare SNP

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- Supplementarydata.docx